Skip to content

Study · Non-randomized trial · n = 204 · 1997

7 results

Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin.

Combe B, Cohen C, Aubin F

Calcified tissue international1 Jul 1997Cited by 24 (Europe PMC)

PMID9192504 (opens in a new tab)DOI10.1007/s002239900284 (opens in a new tab)PepBankPUB-09192504
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with painful vertebral crush fractures, nasal and subcutaneous salmon calcitonin met the specified pain equivalence criterion at D30.

    In plain wordsIn patients with painful vertebral fractures, nasal calcitonin gave equivalent pain results to injected calcitonin.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changePain equivalence at D30
    Study

    n = 204

    Comparator
    50 IU/day subcutaneous salmon calcitonin
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU/day · intranasal · 30 consecutive daysAs given in this study (human).

    Measurements

    95% CI lower difference
    −5.3 mm
    pain at D30
    95% CI upper difference
    7.9 mm
    pain at D30
    Equivalence interval lower bound
    −10 mm
    reference interval
    Equivalence interval upper bound
    10 mm
    reference interval

    Source sentences

    Summary
    The two-sided 95% confidence interval of the difference between the two formulations for the pain on D30 assessed by Huskisson's Visual Analogue Scale (VAS) [-5.3 mm, 7.9 mm] was included in the [-10 mm, 10 mm] reference interval.
    2 context sentences
    Summary · context
    Equivalence of the two formulations, was demonstrated.
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with vertebral fractures, both calcitonin formulations had end-of-study VAS confidence intervals within the clinically pertinent 0-30 mm interval.

    In plain wordsIn patients with vertebral fractures, both calcitonin formulations met the stated end-of-study pain interval.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableEnd-of-study pain
    Study

    n = 204

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU/day intranasal or 50 IU/day subcutaneous · intranasal or subcutaneous · 30 consecutive daysAs given in this study (human).

    Measurements

    VAS interval lower bound
    0 mm
    both treatment groups at study end
    VAS interval upper bound
    30 mm
    both treatment groups at study end

    Source sentences

    Summary
    At the end of the study, the 95% confidence intervals of VAS of both treatment groups were included in the [0 mm, 30 mm] interval, which is considered to be clinically pertinent.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with vertebral fractures receiving calcitonin, more than 50% obtained relief in less than 10 days.

    In plain wordsMore than half of patients with vertebral fractures obtained pain relief in less than ten days during calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicablePain relief responders
    Study

    n = 204

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    200 IU/day intranasal or 50 IU/day subcutaneous · intranasal or subcutaneous · 30 consecutive daysAs given in this study (human).

    Measurements

    Patients with relief
    > 50%
    less than 10 days
    Time to relief
    < 10 days
    more than 50% of patients

    Source sentences

    Summary
    Relief was obtained in less than 10 days for more than 50% of patients.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with vertebral fractures, urinary hydroxyproline/creatinine remained constant from D1 to D30 with both calcitonin formulations.

    In plain wordsIn patients with vertebral fractures, the urinary bone breakdown marker remained constant with both calcitonin formulations.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeUrinary hydroxyproline/creatinine
    Study

    n = 204

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day intranasal or 50 IU/day subcutaneous · intranasal or subcutaneous · 30 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    The urinary hydroxyproline/creatinine and calcium/creatinine ratios remained constant between D1 and D30 with both formulations.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with vertebral fractures, urinary calcium/creatinine remained constant from D1 to D30 with both calcitonin formulations.

    In plain wordsIn patients with vertebral fractures, the urinary calcium ratio remained constant with both calcitonin formulations.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeUrinary calcium/creatinine
    Study

    n = 204

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    200 IU/day intranasal or 50 IU/day subcutaneous · intranasal or subcutaneous · 30 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    The urinary hydroxyproline/creatinine and calcium/creatinine ratios remained constant between D1 and D30 with both formulations.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  6. 06HumanNon-randomized trialSafety outcome

    In patients with vertebral fractures, general safety was comparable between nasal and subcutaneous calcitonin.

    In plain wordsIn patients with vertebral fractures, nasal and injected calcitonin had comparable general safety.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedGeneral safety
    Study

    n = 204

    Comparator
    subcutaneous salmon calcitonin
    Outcome group
    Adverse events · Whole body
    Studied dose
    200 IU/day · intranasal · 30 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    General safety was comparable between the two formulations.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…
  7. 07HumanNon-randomized trialSafety outcome

    In patients with vertebral fractures, local safety of nasal calcitonin was similar to its placebo.

    In plain wordsIn patients with vertebral fractures, nasal calcitonin and nasal placebo had similar local safety.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedLocal safety
    Study

    n: not reported in source

    Comparator
    intranasal placebo
    Outcome group
    Adverse events · Respiratory
    Studied dose
    200 IU/day · intranasal · 30 consecutive daysAs given in this study (human).

    Source sentences

    Summary
    Local safety of INSCT was similar to that of its placebo.
    1 context sentence
    Summary · context
    Two-hundred-four patients, 27 males and 177 females, aged 72 years on average, with a recent, painful, vertebral crush fracture were given either 50 IU/day of subcutaneous salmon calcitonin (SCSCT, 102 patients) or 200 IU/day of intranasal salmon calcitonin (INSCT, 102 patients) for 30 consecutive d…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.